Rapid Health Technology Assessment of the Efficacy,Safety and Economics of Empagliflozin in the Treatment of Type 2 Diabetes Mellitus
10.3870/j.issn.1004-0781.2023.12.017
- VernacularTitle:恩格列净治疗2型糖尿病有效性安全性和经济性的快速卫生技术评估
- Author:
Lu WANG
1
;
Anhua WEI
;
Lu ZENG
;
Ling GUI
;
Xuepeng GONG
;
Dong LIU
Author Information
1. 华中科技大学同济医学院附属同济医院药学部,武汉 430030
- Keywords:
Empagliflozin;
Type 2 diabetes mellitus;
Efficacy;
Safety;
Economic;
Rapid health technology assessment
- From:
Herald of Medicine
2023;42(12):1841-1849
- CountryChina
- Language:Chinese
-
Abstract:
Objective To rapidly evaluate the efficacy,safety and economics of empagliflozin in the treatment of type 2 diabetes mellitus(T2DM)and to provide evidence-based medical evidence for clinical decision.Methods PubMed,Embase,the Cochrane Library,CNKI,Wangfang,VIP database and major health technology assessment(HTA)websites were searched from the construction of the databases to Nov 30th,2022.Two researchers independently screened,extracted the data,evaluated the quality and analyzed the results according to inclusion and exclusion criteria.Results A total of 23 literatures were included,including 3 HTA reports,10 systematic review/Meta-analyses and 10 pharmacoeconomic studies.The results of efficacy showed that empagliflozin reduced HbA1c,blood pressure,body weight and all-cause mortality compared with the control group.Safety studies showed that empagliflozin was generally well tolerated,and significantly reduced MACEs and the relative risk of the renal primary outcomes,but increased the risk of genital infections and electrolyte abnormality compared with placebo and other oral antidiabetic drugs.The economic evaluation results showed that empagliflozin was more cost-effective in high risk patients with comorbid cardiovascular or kidney disease.Conclusion Empagliflozin is effective and safe in the treatment of T2DM,but the pharmacoeconomic studies focusing on chinese populations are urgently needed.
